We are advancing clinical development of two LAT1 inhibitors for biliary tract cancer, multiple sclerosis, and other diseases, while simultaneously progressing discovery research on next-generation compounds.

Biliary tract cancer is diagnosed in approximately 20,000 new patients each year in both Japan and Europe, about 14,000 in the United States, and roughly 44,000 in China. Because early-stage disease presents few noticeable symptoms, many patients are currently diagnosed only after the cancer has progressed.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder most commonly seen in young adults and is designated as an intractable disease by the Ministry of Health, Labour and Welfare of Japan. The average age at diagnosis is relatively young at around 32 years. Globally, more than 60,000 new cases are diagnosed each year...

We are currently focusing our development efforts on nanvuranlat for second-line treatment of biliary tract cancer as a monotherapy and for first-line treatment in combination with immune checkpoint inhibitors, as well as on JPH034 for non-relapsing secondary progressive multiple sclerosis. In addition, we are advancing development programs for KRAS-mutant...